Status:
COMPLETED
Effect of Dexmedetomidine on Perioperative Internal Environment and Rehabilitation of Patients Undergoing Gastrointestinal Malignant Tumor Resection
Lead Sponsor:
Yangzhou University
Conditions:
Dexmedetomidine
Perioperative
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Dexmedetomidine is a highly selective alpha2-adrenergic receptor agonist with sedative, analgesic, anti-anxiety, and inhibitory sympathetic nerve excitation properties. It is commonly used in clinical...
Eligibility Criteria
Inclusion
- American Society of Anesthesiologists (ASA) physical status I or II;
- age between 50-75 years, and a body mass index (BMI) between 18.5-28 kg/m2.
Exclusion
- Patients whoused hormones or drugs that have a hypoglycemic nature during the preoperative state, or had bradycardia, arrhythmia, hypotension, abnormal liver or kidney function, pancreatic disease, neuroendocrine malignancy, intraoperative blood transfusion;
- Patients who refused participation and those who needed intensive care after the surgery were also excluded from the study;
- Patients who had severe internal environmental disorders.
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2020
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT04771637
Start Date
January 1 2017
End Date
August 30 2020
Last Update
November 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the Affiliated Hospital of Yangzhou University
Yangzhou, Jiangsu, China, 225012